Virtual Library

Start Your Search

S.J. Ma



Author of

  • +

    P1.05 - Poster Session with Presenters Present (ID 457)

    • Event: WCLC 2016
    • Type: Poster Presenters Present
    • Track: Early Stage NSCLC
    • Presentations: 1
    • +

      P1.05-033 - Comparison of Single- and Five-Fraction Schedules of Stereotactic Body Radiation Therapy for Central Lung Tumors (ID 4394)

      14:30 - 15:45  |  Author(s): S.J. Ma

      • Abstract
      • Slides

      Background:
      Stereotactic Body Radiation Therapy (SBRT) is a treatment option for patients with early-stage non-small cell lung cancer (NSCLC) who are medically inoperable or decline surgery. The safety of 20 Gray (Gy) x 3 fractions of SBRT within 2 cm of the proximal bronchial tree is unclear. Here we compare the clinical outcome of patients with centrally located lung tumors who underwent either single fraction (SF)- or five-fraction (FF-) SBRT at a single institution over 5 years.

      Methods:
      Between January 2009 and October 2014, 11 out of 42 patients received 26-30 Gy in 1 fraction, while the remaining 31 patients received 52.5-60 Gy (median 55 Gy) in 5 fractions. Data were retrospectively collected using an institutional review board-approved database. Kaplan-Meier method, competing risks method, and Cox regression model were used. Toxicities were graded using Common Terminology Criteria for Adverse Events version 4.0. R version 3.3.1 was used for statistical analysis.

      Results:
      After a median follow-up of 12 months for SF-SBRT and 17 months for FF-SBRT groups (p=0.64), 1-year overall survival rates for SF- and FF-SBRT groups were 82% and 87%, respectively. There was no statistically significant difference in overall survival (p=0.061), progression-free survival (p=0.47), local failure (p=0.43), nodal failure (p=0.42), and distant failure (p=0.45) at 18 months. No primary tumor failure was seen in both groups at 18 months. Distant failure rates at 18 months were 9.1% for SF-SBRT group and 54.5% for FF-SBRT group. Among the patients with distant failure (n=4 in SF-SBRT and n=6 in FF-SBRT), median time to distant failure was 29.5 months and 8.9 months for SF- and FF-SBRT groups, respectively (p=0.0095). 3 out of 11 patients in SF-SBRT group and 2 out of 32 patients in FF-SBRT group experienced grade 3-4 toxicities. No grade 4-5 toxicities were observed in the FF-SBRT group. SF-SBRT group showed higher cumulative incidence of grade 3+ toxicity at 18 months (p=0.018). However, univariate analysis showed SF-SBRT alone was not a significant factor that increased risk for grade 3+ toxicities (HR=5.50, p=0.063). 4 out of 5 toxicities occurred at least 12 months after SBRT.

      Conclusion:
      SF- and FF-SBRT showed no significant difference in overall survival and local control. No grade 4-5 toxicities were observed in our FF-SBRT group. The onset of distant failure was significantly delayed in the SF-SBRT compared to the FF-SBRT group. The majority of toxicities occurred late. Having SF-SBRT itself was not significantly associated with severe toxicity.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.